Insider Shareholders with Direct Ownership of Revance Therapeutics, Inc. (RVNC)
This section provides a comprehensive overview of the insiders with direct ownership of Revance Therapeutics, Inc. (RVNC). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Revance Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Mark J Foley
CEO |
1,185,096 | 602,661 | 995,935 $2.56 Million | 27 |
Jun 30, 2024
Added 0.1%
|
|
Tobin Schilke
CFO |
264,958 | 110,850 | 193,666 $497,721 | 38 |
Jun 30, 2024
Added 0.51%
|
|
Dustin S Sjuts
President |
229,660 | 96,174 | 167,550 $430,603 | 30 |
Mar 18, 2024
Reduced 5.21%
|
|
Dwight Moxie
CLO & GC |
240,783 | 127,968 | 137,815 $354,184 | 20 |
Mar 18, 2024
Reduced 5.57%
|
|
Abhay Joshi
COO, President of R&D |
40,120 | 21,244 | 120,708 $310,219 | 7 |
Mar 15, 2022
Reduced 2.11%
|
|
Erica Jordan
Chief Commercial Officer |
0 | 2,392 | 114,864 $295,200 | 1 |
Apr 16, 2024
Reduced 2.04%
|
|
David Hollander
CMO & Global Therapeutics Lead |
0 | 3,908 | 104,945 $269,708 | 1 |
Nov 18, 2024
Reduced 3.59%
|
|
Aubrey Rankin
Director |
41,905 | 15,685 | 94,091 $241,813 | 5 |
Mar 15, 2022
Reduced 1.44%
|
|
Angus C. Russell
Director |
35,006 | 0 | 51,506 $132,370 | 5 |
May 01, 2024
Added 22.55%
|
|
Julian S Gangolli
Director |
28,606 | 0 | 45,106 $115,922 | 4 |
May 01, 2024
Added 24.96%
|
|
Jill Beraud
Director |
28,606 | 0 | 43,606 $112,067 | 4 |
May 01, 2024
Added 25.59%
|
|
Chris Nolet
Director |
28,606 | 0 | 43,606 $112,067 | 4 |
May 01, 2024
Added 25.59%
|
|
Olivia C Ware
Director |
31,675 | 0 | 31,675 $81,404 | 5 |
May 01, 2024
Added 32.14%
|
|
Carey O Connor Kolaja
Director |
34,061 | 2,500 | 31,561 $81,111 | 7 |
May 01, 2024
Added 32.22%
|
|
Philip J. Vickers
Director |
10,072 | 0 | 29,722 $76,385 | 2 |
May 04, 2022
Added 16.93%
|
|
Vlad Coric
Director |
20,784 | 0 | 20,784 $53,414 | 3 |
May 01, 2024
Added 41.92%
|